Effector Therapeutics Performance
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Effector Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Effector Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Effector Therapeutics is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 8.7 M |
Effector |
Effector Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in Effector Therapeutics on December 24, 2024 and sell it today you would earn a total of 100.00 from holding Effector Therapeutics or generate -100.0% return on investment over 90 days. Effector Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Effector, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Effector Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Effector Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Effector Therapeutics, and traders can use it to determine the average amount a Effector Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| EFTR |
Based on monthly moving average Effector Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Effector Therapeutics by adding Effector Therapeutics to a well-diversified portfolio.
Effector Therapeutics Fundamentals Growth
Effector Stock prices reflect investors' perceptions of the future prospects and financial health of Effector Therapeutics, and Effector Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Effector Stock performance.
| Return On Equity | -9.47 | ||||
| Return On Asset | -0.83 | ||||
| Current Valuation | (4.52 M) | ||||
| Shares Outstanding | 4.7 M | ||||
| Price To Earning | 1.03 X | ||||
| Price To Book | 13.38 X | ||||
| Price To Sales | 69.65 X | ||||
| EBITDA | (33.73 M) | ||||
| Cash And Equivalents | 41.04 M | ||||
| Cash Per Share | 0.99 X | ||||
| Total Debt | 19.45 M | ||||
| Debt To Equity | 1.03 % | ||||
| Book Value Per Share | 0.21 X | ||||
| Cash Flow From Operations | (29.55 M) | ||||
| Earnings Per Share | (12.57) X | ||||
| Total Asset | 20.54 M | ||||
| Retained Earnings | (179.38 M) | ||||
Things to note about Effector Therapeutics performance evaluation
Checking the ongoing alerts about Effector Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Effector Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Effector Therapeutics is not yet fully synchronised with the market data | |
| Effector Therapeutics has some characteristics of a very speculative penny stock | |
| Effector Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (35.81 M) with loss before overhead, payroll, taxes, and interest of (19.76 M). | |
| Effector Therapeutics currently holds about 41.04 M in cash with (29.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99. |
- Analyzing Effector Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Effector Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Effector Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Effector Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Effector Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Effector Therapeutics' stock. These opinions can provide insight into Effector Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Effector Stock
If you are still planning to invest in Effector Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Effector Therapeutics' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |